Skip to main content

Table 6 Comparison of the literatures for helical tomotherapy in patients with unresectable hepatocellular carcinoma

From: Feasibility and efficacy of helical tomotherapy in cirrhotic patients with unresectable hepatocellular carcinoma

Reference No. Fraction size (Gy) Total dose (Gy) Target of RT Response (%) Median Survival (months) RILD (%) Grade III toxicity Combined therapy
McIntosh [19] 20 2.5 50 PVTT(+) 40 % PR 6.2 9.6 N/A UGI bleeding 1/20 Capecitabine
    PVTT(−) 60 % SD 87.5     
Chi [34] 23 2.5–4.5 52.5 (median) N/A CR 8.6 16 1/23 UGI bleeding 2/23 Sunitinib
     PR 65.4    Hematology 6/23  
Kim [14] 35 4.5–6 50 (range, 45–60) PVTT(+) 100 % CR 14.3 12.9 0/35 GI bleeding 2/35 Capecitabine
     PR 28.6 Responder 13.9   Hematology 3/35  
      Non-responder 6.9    
Kong [15] 20 1.8–4 50–57.5 (range, 30–60) PVTT(+) 36.4 % CR 18.2 14.4 1/20 None None
    PVTT(−) 63.6 % PR 54.5 Responder 87.8a    
       Non-responder 65.6a    
Current study 38 1.8–2.4 54 (range, 46–71.8) PVTT(+) 63.2 % CR 5.2 12.6 1/38 1/38 None
    PVTT(−) 36.5 % PR 47.4 Responder 27.8    
       Non-responder 6.2    
  1. RT radiation therapy, PVTT portal vein tumor thrombus, N/A no data, CR complete response, PR partial response, SD stable disease, RILD radiation-induced liver disease, GI gastrointestinal
  2. a1-year overall survival rate (%)